![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 41, 28880-28886, October 8, 1999
From the Structural microdomains of G protein-coupled
receptors (GPCRs) consist of spatially related side chains that mediate
discrete functions. The conserved helix 2/helix 7 microdomain was
identified because the gonadotropin-releasing hormone (GnRH) receptor
appears to have interchanged the Asp2.50 and
Asn7.49 residues which are conserved in transmembrane
helices 2 and 7 of rhodopsin-like GPCRs. We now demonstrate that
different side chains of this microdomain contribute specifically to
receptor expression, heterotrimeric G protein-, and small G
protein-mediated signaling. An Asn residue is required in position
2.50(87) for expression of the GnRH receptor at the cell surface, most
likely through an interaction with the conserved
Asn1.50(53) residue, which we also find is required for
receptor expression. Most GPCRs require an Asp side chain at either the
helix 2 or helix 7 locus of the microdomain for coupling to
heterotrimeric G proteins, but the GnRH receptor has transferred the
requirement for an acidic residue from helix 2 to 7. However, the
presence of Asp at the helix 7 locus precludes small G
protein-dependent coupling to phospholipase D. These
results implicate specific components of the helix 2/helix 7 microdomain in receptor expression and in determining the ability of
the receptor to adopt distinct activated conformations that are optimal
for interaction with heterotrimeric and small G proteins.
The gonadotropin-releasing hormone
(GnRH)1 receptor belongs to
the rhodopsin-like family of G protein-coupled receptors (GPCR) (1).
This family includes the light-sensitive opsins, protease-activated receptors, and receptors for neurotransmitters, peptides, and glycoproteins. High resolution structural data have not yet been obtained for any GPCR. However, projection maps of rhodopsin, amino
acid sequence alignment, and computational modeling indicate that GPCRs
have 7 membrane-spanning Several models of GPCRs, including the GnRH receptor (4, 8), have been
constructed as aids for investigating receptor structure-function
relations. Molecular models of GPCRs can be used to integrate
experimental observations and generate structural hypotheses. However,
the complexity of these structures and the limited number of
experimentally determined constraints can lead to inconsistent behavior
of the models (4, 7). To overcome these limitations, we have pursued
the approach of identifying discrete structural motifs within receptor
models, which might constitute functional microdomains. The
microdomains are characterized in detail and subsequently incorporated
into whole receptor models. In the GnRH receptor, for example, this
approach has recently been used to propose that the motion of the
conserved Arg3.50(139) side chain is restricted by
interaction with the conserved Asp3.49(138) and the
presence of a A related GPCR structural motif consists of this H7 side chain (usually
Asn7.49) and the conserved 2.50 residue (usually Asp) in
H2. The H2/H7 microdomain was originally identified from the apparent
interchange of these side chains in the GnRH receptor and its
functional importance was supported by reciprocal mutagenesis studies
(8). Reciprocal mutation experiments in the serotonin
5-HT2A (9), thyrotropin releasing hormone (TRH)
(10), µ opioid (11), and NK2 tachykinin receptors (12)
have all shown that the disruption of signal transduction observed with
mutation of the Asp2.50 side chain in H2 is restored by a
second mutation in H7 that interchanges the two conserved residues.
While the inter-related roles of these H2 and H7 side chains in
receptor activation (9-12) suggest that they constitute a structural
and functional microdomain, this conclusion has been considered
controversial (13, 14). The initial study of this microdomain in the
GnRH receptor reported that the presence of an Asp residue in both loci
eliminated detectable binding. This result raised the possibility that
charge repulsion was responsible for the observed phenotype. However,
the presence of Asp at both positions in wild-type non-mammalian GnRH
receptors (15, 16) and in several other GPCRs (3) as well as in
functional mutant GPCRs (9, 10, 14, 17) indicates that the side chains in this microdomain, that are compatible with function, differ among GPCRs.
For a specific receptor, the side chains of the H2/H7 microdomain may
contribute to receptor expression and receptor activation and coupling
to intracellular signal transduction. The molecular events that
underlie receptor activation are a key question in understanding
receptor function. Studies of many receptors have implicated the H2/H7
microdomain as a key component of this process (9-11, 18). The
involvement of this domain in multiple distinct receptor functions may
account for the different results observed in the various receptors
studied. The side chain at the 7.49 locus has also recently been
implicated in specifying small G protein-dependent coupling
to PLD (19). In order to elucidate the role of this microdomain in the
GnRH receptor, we have investigated the functional requirements of each
locus in receptor expression, coupling to heterotrimeric G
protein-dependent signal transduction, and coupling to the
small G protein, ADP-ribosylation factor (ARF).
Amino Acid Residue Numbering--
To allow comparison of
equivalent residues in different GPCRs, amino acids in the
transmembrane segments of the GnRH receptor are numbered relative to
the most conserved residue of the rhodopsin-like GPCRs, as described
previously (7). Thus, Asn87, which is located in the
position of the most conserved residue in H2, is designated
Asn2.50(87), while Asp318, which is adjacent to
the most conserved residue in H7 (Pro7.50(319)), is
designated Asp7.49(318).
DNA Constructs, Cell Culture, and Transfection--
The
mutations N2.50(87)D, N2.50(87)Q, N2.50(87)A, D7.49(318)N, D7.49(318)E,
and D7.49(318)A were introduced into the mouse GnRH receptor as
described previously (8) using the Altered Sites Mutagenesis System
(Promega, Madison, WI), while the mutations N1.50(53)A, N1.50(53)D,
N1.50(53)L, and D7.49(318)L were generated using QuikChange
(Stratagene, La Jolla, CA). Two epitope tags were applied to the GnRH
receptor to allow detection of the receptor by Western blotting. An
amino-terminal HA-tag (YPYDVPDYA) was inserted after the initial Met
residue of the wild-type GnRH receptor by polymerase chain reaction.
Since the mouse GnRH receptor does not have a cytosolic
carboxyl-terminal domain, a carboxyl-terminal domain derived from a
putative human type II GnRH receptor (20) was appended to allow
addition of a carboxyl-terminal hexahistidine tag using a combination
of polymerase chain reaction and multifragment subcloning into the
pcDNA3 expression vector (Invitrogen, San Diego, CA). The
carboxyl-terminal seven amino acids of the carboxyl-terminal domain
were substituted with six histidine residues to generate a
hexahistidine tag. All DNA constructs were sequenced to confirm the
presence of mutations and epitope tags.
COS-1 cells were maintained in Dulbecco's modified Eagle's medium
containing 10% fetal bovine serum and transfected as described previously, using LipofectAMINE (Life Technologies Inc., Gaithersburg, MD) (21). Cells to be used for intact cell functional assays were
seeded into 12- or 24-well plates the day after transfection.
Ligand Binding
Assays--
[D-Ala6,Pro9-NHEt]GnRH
(GnRH-A, Bachem, Torrance, CA), was radioiodinated using IODO-GEN
(Pierce Chemical Co., Rockford, IL) following published protocols (22).
Whole cell binding assays were performed as described (23). Briefly,
transfected cells, in 24-well plates, were incubated for at least
2 h at 4 °C with 125I-GnRH-A (60,000 cpm/well) and
varying concentrations of unlabeled GnRH-A or GnRH (Bachem, Torrance,
CA) in a total volume of 0.4 ml/well. The incubation was terminated by
removal of the medium and bound radioactivity was collected in 1 M NaOH. Nonspecific binding was determined in the presence
of 10
Membrane binding assays were performed as described previously (24) on
some low-expressing constructs because this method makes it possible to
increase receptor concentration in the assay by varying the amount of
membrane added to incubation tubes. Cell membranes were resuspended in
protein-free binding buffer (1 mM EDTA, 10 mM
HEPES, pH 7.5) and incubated for 90 min on ice with 125I-GnRH-A (200,000 cpm), 0.1% bovine serum albumin and
varying concentrations of GnRH-A. The reaction was terminated by
filtration through GF/C filters (Brandel Inc., Gaithersberg, MD) which
were presoaked in binding buffer containing 1% bovine serum albumin, and washed twice with binding buffer.
Immunoblotting--
Transfected cells (9-cm dishes) were washed
with phosphate-buffered saline prior to harvesting and homogenization
in lysis buffer (50 mM Tris, pH 7.5, 1 mM
phenylmethylsulfonyl fluoride, 1 mM EDTA, and 10 µg/ml
leupeptin). The homogenate was centrifuged for 10 min at 500 × g and 4 °C and the resulting supernatant was centrifuged
at 35,000 × g for 20 min at 4 °C. The membrane
pellet was resuspended in lysis buffer (30 µl/3 × 106 transfected cells) and solubilized by gentle shaking
for 15 min on ice in the presence of CHAPS at a final concentration of
15 mM. The solubilization mixture was centrifuged for 30 min at 35,000 × g and 4 °C to remove particulate
material, and the resulting supernatant was incubated with
N-glycosidase F (Roche Molecular Biochemicals, Indianapolis,
IN, 0.2 units per 20 µl of supernatant) for 30 min at 37 °C.
Samples were electrophoresed under reducing conditions on NuPAGE
polyacrylamide gels (Novex, San Diego, CA) according to the
manufacturer's instructions and electroblotted onto nitrocellulose
membranes (Hybond C Pure, Amersham Pharmacia Biotech) in the presence
of 0.04% SDS. Blots were blocked for at least 1 h in blot buffer
(5% non-fat dry milk, 20 mM Tris, pH 7.5, 150 mM NaCl) before incubation overnight in Tetra-His antibody
(Qiagen, Valencia, CA, 0.2 µg/ml in blot buffer). Bound antibody was
detected using the ECL Western blotting kit (Amersham Pharmacia Biotech).
Phosphatidylinositol Hydrolysis--
Accumulation of inositol
phosphates (IP) in the presence of Li+ was determined
according to published protocols (25). Transfected cells were labeled
for 16 h in Dulbecco's modified Eagle's medium containing 0.5 µCi/ml myo-[3H]inositol (NEN Life Science
Products, North Billerica, MA). After washing with serum-free medium
the cells were incubated for 45 min at 37 °C with varying
concentrations of GnRH in the presence of 20 mM LiCl. The
incubation was terminated by removal of the medium and addition of 10 mM formic acid. [3H]IP was separated from the
formic acid extracts on Dowex-1 ion-exchange columns and eluted with 1 M ammonium formate and 0.1 M formic acid.
PLD Assay--
Activation of PLD was determined by a
transphosphatidylation assay as described previously (26). Transfected
cells in 12-well plates were labeled overnight with
[3H]palmitate in serum-free minimum essential medium.
After washing with minimal essential medium containing HEPES (25 mM, pH 7.5) and 1% fatty acid-free bovine serum albumin,
cells were preincubated for 30 min at 37 °C with various
concentrations of brefeldin A (BFA) in HEPES-buffered minimal essential
medium with 0.5% bovine serum albumin, before addition of butan-1-ol
(30 mM) and GnRH (1 µM) and incubation for a
further 30 min. Reactions were terminated by removal of the medium and
addition of 0.5 ml of cold methanol to each well. Phospholipids were
extracted and separated on Whatman LK5D thin layer chromatography
plates as described (26).
Data Analysis--
Kd and
Bmax values for binding of GnRH-A were
determined using the LIGAND computer program (27). Protein levels were
determined by the Lowry method. IC50 (concentration
required for 50% inhibition of 125I-GnRH-A binding) values
for GnRH were estimated using nonlinear curve fitting (KaleidaGraph,
Synergy Software, Reading, PA). EC50 (agonist concentration
required for half-maximal response) values for IP production were
calculated using KaleidaGraph. IP data were fitted to the equation
E = Emax/(1 + EC50/D), where the Emax is the maximum IP accumulation and D is the concentration of
the agonist. Transient transfection of the wild-type GnRH receptor into
COS-1 cells leads to expression of an appreciable level of "spare
receptors" which results in an EC50 for IP accumulation that is significantly lower than the Kd for GnRH
binding to the receptor (21). Because of the receptor reserve in the wild-type receptor and the varied expression levels of the mutant receptors, simple comparison of maximal IP accumulation does not yield
an accurate measure of how well a particular receptor is activated. To
facilitate comparison of mutant receptor activation, we have utilized a
previously derived expression of receptor coupling efficiency,
Q, which is defined as: Q = 0.5 × [(Kd + EC50)/EC50] × (Emax/Bmax) (4).
IC50 values for GnRH were used as an approximation of
Kd.
H2 Mutants Are Not Expressed, but Expression Is Restored in H2/H7
Reciprocal Mutant--
The effects of amino acid substitutions at each
locus of the H2/H7 microdomain were studied. The substitutions
introduced for Asn2.50(87) (Gln, Asp, and Ala) were
designed to test the effects of altered size, charge, and polarity on
receptor function. None of the single H2 mutant constructs studied
exhibited detectable ligand binding activity, IP accumulation, or
ARF-dependent accumulation of phosphatidyl butanol (PtdBut)
(Table I).
To determine whether the lack of ligand binding by the H2 mutants
resulted from altered receptor expression, we utilized an immunoblot
assay of epitope-tagged receptor constructs. The parent epitope-tagged
construct had an amino-terminal HA-tag and a carboxyl-terminal domain
with a hexahistidine tag (see "Experimental Procedures"). The
effects of epitope tagging on receptor function were evaluated. All H2
and H7 mutant constructs were epitope-tagged and tested in ligand
binding and IP accumulation assays. The tagged wild-type and mutant
receptors mediated IP accumulation with EC50 values which
were comparable to those of corresponding untagged receptors. For all
constructs with measurable ligand binding, Kd values
were unchanged and Bmax values elevated with
epitope tagging. As was observed for the untagged receptors, ligand
binding was not detectable in the epitope-tagged N2.50(87)D and
N2.50(87)A constructs (Table II). The
epitope-tagged N2.50(87)Q construct exhibited low, but measurable
ligand binding (Table II). This tagged construct also mediated a low
level of GnRH-stimulated IP accumulation (not shown). The relative
receptor expression, as measured by ligand binding, and the function of
the tagged receptors closely paralleled that of the untagged receptors,
thus validating the use of the tagged receptors in protein expression assays.
Western blots of the epitope-tagged wild-type receptor yielded a broad
band of 55-85 kDa (not shown) which was compressed to a single band at
34 kDa after deglycosylation (Fig. 1).
This pattern resembles that reported for the photoaffinity-labeled GnRH
receptor (28). To increase sensitivity of detection and facilitate
comparison of band intensity, all receptors were deglycosylated prior
to immunoblot analysis. At a level of sensitivity which yielded an
intense band for the epitope-tagged wild-type receptor, only a faint
signal was visible for the H2 mutants in which Asn2.50(87)
was substituted with Asp, Gln, or Ala (Fig. 1). Thus, the low or absent
binding and coupling of these constructs is associated with very low
levels of receptor protein.
In contrast to the results obtained with single H2 mutants, the
reciprocal mutant, N2.50(87)D/D7.49(318)N, exhibited ligand binding
(Table I), as described previously (8). In addition, this receptor was
also clearly visible on immunoblot analysis, yielding a band which had
lower intensity than that of the wild-type receptor (Fig. 1).
Differing Expression of H7 Mutants--
The functions of GnRH
receptors with Asp7.49(318) mutated to Asn, Glu, and Ala
were studied to evaluate the role of size, hydrogen bonding, and ionic
interactions at this locus. All of these H7 mutants bound GnRH-A with
affinities similar to that of the wild-type receptor (Fig.
2, Table I). The maximal binding of these
constructs varied, with Asp (wild-type) H1 Mutants Are Not Expressed, and the H1/H7 Reciprocal Mutant Does
Not Restore Expression--
The high expression of the non-polar H7
mutant, Ala7.49(318), shows that the low expression of the
H2 mutants is not due to loss of an interaction with the H7 side chain.
It has been proposed, for other GPCRs, that the 2.50 side chain
interacts with the highly conserved Asn1.50 side chain in
H1 (10, 18). To test whether the low expression of the H2 mutants might
be due to disruption of an interaction with Asn1.50(53) in
the GnRH receptor, this residue was mutated to Asp, Ala, and Leu. All
H1 mutant constructs exhibited no measurable ligand binding or
GnRH-stimulated accumulation of IP (Table I) and yielded only faintly
detectable bands on immunoblots (Fig. 1). A reciprocal mutant,
N1.50(53)D/D7.49(318)N, was constructed to test whether the locus 7.49 side chain influences the function of the Asn1.50(53) side
chain. This reciprocal mutant showed no recovery of the ligand binding
and IP accumulation which is lost in the H1, N1.50(53)D single mutant
(Table I).
Phospholipase C (PLC) Activation--
While all of the H7 mutants
(except for Leu7.49(318)) were capable of mediating
GnRH-stimulated IP production, the EC50 values were increased and Emax values decreased in
comparison with the wild-type GnRH receptor (Fig.
3A, Table I). The magnitude of
IP stimulation observed did not correlate with levels of mutant
receptor expression. For example, the D7.49(318)A construct, which
expressed at wild-type levels, exhibited low maximal IP response (12%
of wild-type Emax). In contrast, the poorly
expressed D7.49(318)E mutant showed a relatively high IP signal (36.6%
of wild-type Emax). These results reveal
distinct side chain requirements for expression and for coupling to
PLC.
An empirical measure of receptor coupling efficiency that estimates the
functional response achieved per agonist-occupied receptor was
calculated for each construct, as described previously (4) (see
"Experimental Procedures"). The rank order of coupling efficiency
for PLC was: wild-type, Asp > Glu > Asn > reciprocal H2D/H7N > Ala (Fig. 3B, Table I). It was not possible
to calculate coupling efficiency for the D7.49(318)L mutant because of
its lack of measurable binding and IP accumulation. The low efficiency of the Ala and Asn mutants indicates the importance of the polar and
ionic functions of the native Asp side chain in PLC coupling. However,
the high efficiency of the D7.49(318)E construct shows that a
carboxylate side chain is required for efficient coupling to PLC.
It is notable that the PLC coupling efficiency of the reciprocal mutant
(with Asp in H2, Asn in H7) was lower than for the D7.49(318)N single
mutant (Table I, Fig. 3B). In other PLC-coupled GPCRs,
mutants containing Asn residues at both the 2.50 and 7.49 loci were
poorly coupled (9, 10), a result which we also see in the GnRH receptor
(Table I). However, in contrast to the other GPCRs studied, where
reciprocal mutation restored coupling (9, 10), the GnRH receptor
appears unique in that the poor coupling persists with the interchange
mutations. These commonalties and differences have implications for
understanding the pattern of intramolecular signal transduction
associated with GnRH receptor activation (see "Discussion"). They
may also represent the special properties or importance of an Asp side
chain in H7 in the GnRH receptor (18), which is present in the
wild-type receptor in species from bony fish to mammals.
PLD Activation--
We have recently reported that the
BFA-sensitive component of PLD activation depends on receptor
interaction with small G proteins in the ARF/RhoA family (19). GnRH was
found to stimulate PtdBut accumulation via the wild-type receptor and
all of the H7 mutants (Fig. 4, Table I).
However, only the response mediated by the D7.49(318)N mutant and the
N2.50(87)D/D7.49(318)N reciprocal mutant exhibited the BFA sensitivity
characteristic of coupling to the small G protein, ARF (Fig. 4, Table
I). Thus, in contrast to heterotrimeric G-protein coupling, coupling to
ARF appears to have a stringent requirement for an Asn residue at
position 7.49. This requirement may relate to stabilization of
different activated receptor conformations when the side chain at this
position is varied (see "Discussion").
The H2/H7 microdomain of the GnRH receptor is unusual among GPCRs
in having an Asn residue at position 2.50(87). Our study of the role of
each side chain of the microdomain in distinct GnRH receptor functions
supports the importance of this structural microdomain and reveals the
elements of the microdomain that are necessary for each function. The
Asn in H2 is required for stable receptor expression and the Asp in H7
is critical both for efficient coupling to PLC and for excluding
ARF-dependent coupling to PLD.
Requirement for Asn2.50(87) in Receptor
Expression--
All mutations of the Asn residue in H2 profoundly
disrupted receptor expression. This resulted in a loss of signal in
ligand binding assays, second messenger determination, and immunoblot analysis. The immunoblot results indicate that the loss of
receptor-binding sites for the H2 mutants most likely results from a
decrease in membrane receptor protein. Mutations that led to
intracellular retention of receptor (29) and receptor protein
instability (30) have been reported for the
The requirement for an Asn2.50(87) residue in H2 for
expression is an unusual feature of the GnRH receptor. Furthermore, the
detrimental effect of the simultaneous presence of Asp at both the 2.50 and 7.49 loci on receptor expression is not observed in most other GPCRs studied (9, 10, 12, 17, 31). Incorporation of a second Asp
residue in the H2/H7 microdomain, by mutating the Asn7.49
residue to Asp in the 5-HT2A, TRH, cholecystokinin B
(CCKB), and NK2 receptors, which have Asp at
position 2.50, caused relatively modest decreases in receptor
Bmax levels (9, 10, 12, 14). Only the µ-opioid
receptor is similar to the GnRH receptor in manifesting complete loss
of binding with Asp present at both the H2 and H7 loci (11). The
ability of some GPCRs to tolerate Asp side chains at both loci has led
some workers to conclude that the H2 and H7 side chains are unlikely to
be in close proximity (14). However, crystallographic studies reveal
that Asp side chains can occur in close proximity within proteins and
can form hydrogen bonds when one of the Asp side chains is protonated
(32, 33). Thus, the tolerance of Asp residues at both loci in various GPCRs does not exclude proximity of the side chains of the H2/H7 microdomain. Differences in the complement of amino acids that constitute the microenvironment of this domain in different receptors most likely determine the specific side chains that are tolerated at
each position. The present results and data from all other GPCRs
studied are consonant with spatial proximity of the conserved H2 and H7
side chains.
In view of the profound decrease in expression observed with
substitutions for Asn2.50(87), it is difficult to draw firm
conclusions from mutagenesis studies about the role of this side chain
in receptor coupling. The detection of some receptor function with the
epitope-tagged N2.50(87)Q mutant suggests that preserving a polar amide
side chain at this position may preserve receptor function to a greater
extent than the other substitutions tested. While a role of
Asn2.50(87) in receptor activation cannot be inferred from
the present data, such a role would be consistent with previously
reported computational studies which suggest that both
Asn2.50(87) and Asp7.49(318) interact with the
conserved Arg3.50(139) side chain to stabilize the active
state of the receptor (4).
H7 Side Chain at the 7.49 Locus Is Not Required for Receptor
Expression--
We have demonstrated that restoration of GnRH receptor
binding with the reciprocal mutation, N2.50(87)D/D7.49(318)N, is
accompanied by restoration of receptor expression, as determined by
immunoblotting. These results suggest that the strict requirement for
Asn in position 2.50 can be satisfied by insertion of an amide side
chain in the spatially adjacent 7.49 locus. Alternatively, a charged
Asp side chain can substitute for the Asn2.50(87) side
chain in the GnRH receptor when a destabilizing interaction with the H7
side chain is removed by substitution of the charged Asp7.49(318) residue with an uncharged Asn residue. The
relatively high expression of the D7.49(318)A mutant indicates that a
direct interaction between the 2.50 and 7.49 side chains is not
required for receptor expression. This mutant was the best expressed of
the mutant receptors in this study, but since the side chain of Ala is
non-polar, it cannot form a hydrogen bond with the residue in position
2.50. It has been proposed that the Asp2.50 side chain of
the TRH receptor forms hydrogen bonds with both the Asn7.49
side chain and the highly conserved Asn1.50 side chain in
H1 (10). The Asn1.50(53) residue is conserved in the GnRH
receptor and, based on computational modeling (4, 8), could interact
with the Asn2.50(87) side chain. Our results showing that
an interaction with Asp7.49(318) is not required for
expression of the GnRH receptor, suggested that an interaction between
the side chains of Asn2.50(87) and Asn1.50(53)
may be required for stable receptor expression. Mutation of
Asn1.50(53) to Ala, Asp, or Leu also yielded constructs
with very low expression, similar to the H2 mutants. The similar
phenotypes of mutants with subtle changes in H1 or H2 is consistent
with, and supports a role for a hydrophilic interaction between these
side chains in stabilizing expression of the GnRH receptor. A
reciprocal mutant, N1.50(53)D/D7.49(318)N, did not recover the function
lost in the H1 mutants, showing that the H7 side chain does not
influence the function of the H1 side chain in the same way as it does
the H2 side chain. This is consistent with molecular models which show
polar interactions of the 2.50 side chain with the 1.50 and 7.49 side
chains, but no direct interaction between the 1.50 and 7.49 loci (7,
10, 18, 34).
The high levels of expression observed with mutations of the
Asp7.49(318) to either Asn or Ala indicate that the
functional features of the Asp side chain are not required for
efficient receptor expression. In fact, the H7 mutant which preserves
the acidic group, D7.49(318)E, had much lower expression than receptors
with Ala or Asn substitutions at this position. These data reveal that
expression is sensitive to the length of the negatively charged side
chain at position 7.49. These results suggest that a larger side chain
at position 7.49 may interfere with receptor assembly, either through
steric interference that would disrupt helix packing due to increased bulk of the side chain, or through a disruption of protein folding by
misalignment of the carboxyl group. To determine whether the detrimental effect of the Glu7.49(318) mutation on receptor
function was due to the increased bulk of the side chain or to
unfavorable positioning of the carboxyl group, Asp7.49(318)
was mutated to Leu. The low expression of this mutant indicates that
the receptor cannot accommodate a bulky side chain in this position.
Acidic Side Chain Required at Locus 7.49 for Efficient Activation
of PLC--
In contrast to the poor expression seen with the mutation
of Asp7.49(318) to Glu, the PLC coupling efficiency of this
mutant is comparable to that of the wild-type receptor (Table I, Fig.
3B). In contrast, the D7.49(318)A mutant was well expressed
and yet was nearly uncoupled from PLC activation (Table I, Fig. 3). The
preservation of the PLC coupling efficiency of the D7.49(318)E mutant,
which conserves the negative charge of the Asp side chain, indicates
that a carboxylate side chain is necessary for efficient activation of
heterotrimeric G proteins. The rank order of the coupling efficiency of
mutants with H7 side chain substitutions, Asp > Glu > Asn > Ala, is consistent with the involvement of ionic and
hydrogen bonds in the interactions of these side chains with the highly
conserved Arg3.50(139) residue. These data are consistent
with our proposal that an interaction between the
Arg3.50(139) and Asp7.49(318) side chains
stabilizes receptor activation (4).
The amino acid side chains in the H2/H7 microdomain of the GnRH
receptor that are required for efficient coupling to heterotrimeric G
proteins differ from those required in other GPCRs. In GPCRs which have
the canonical wild-type Asp-Asn arrangement of the microdomain, the
Asp2.50 side chain is required for efficient G protein
coupling (9, 10, 12, 14, 31). In addition, a polar residue is required in H7. Mutation of Asn7.49 to Ala significantly uncoupled
the
The non-mammalian GnRH receptors have Asp residues in both the H2 and
H7 loci (15, 16). The presence of the two Asp residues in these
receptors raises the possibility that the non-mammalian GnRH receptors
represent evolutionary intermediates between the conserved Asp-Asn
arrangement found in most GPCRs and the Asn-Asp arrangement found in
all mammalian GnRH receptors (1). Like the mammalian GnRH receptor, the
non-mammalian, catfish receptor exhibited decreased coupling when the
Asp residue in H7 was mutated to Asn (15). As in the present study,
lack of ligand binding activity prevented analysis of H2 mutants of the
catfish GnRH receptor (15), so it is not possible to determine whether
the carboxylate function of the H2 Asp side chain is required for coupling of the non-mammalian GnRH receptor. In contrast, the platelet
activating factor receptor, which also has Asp residues at both loci,
retained coupling to PLC when the H7 Asp residue was mutated, but was
uncoupled when the H2 Asp residue was mutated (36), showing that this
receptor retains its Asp residue coupling function in H2.
Asn7.49(318) Required for ARF-mediated Activation of
PLD--
Computational simulations of agonist binding to the wild-type
and D2.50N mutant serotonin 5HT2A receptors showed that
agonist binding induces a conformational rearrangement of the mutant
receptor which is different from the agonist-induced conformation of
the wild-type receptor (9). This suggests that mutant GPCRs that do not
have an Asp residue in the H2/H7 microdomain are able to assume an
activated conformation, but that this conformation is different from
the activated conformation of the wild-type receptors that have an Asp
residue in this microdomain. Mutation of the Asp2.50 side
chain has variable effects on signal transduction in different receptors (9, 31). Mutating the Asp2.50 residue of the
The GnRH receptor mutants which lack an acidic residue in the H2/H7
microdomain were poorly coupled to activation of PLC. In contrast, the
D7.49(318)N mutant and the N2.50(87)D/D7.49(318)N reciprocal mutant
gained the capacity to mediate ARF-dependent activation of
PLD (Table I, Fig. 4). Furthermore, as previously demonstrated, the
reciprocal mutant (N2.50(87)D/D7.49(318)N) also shows a pattern of
PtdBut accumulation characteristic of ARF-dependent signaling (19). Thus, mutant receptors which do not efficiently adopt
the activated conformation necessary for activation of heterotrimeric G
protein-dependent signaling were, nevertheless, able to
activate the small G protein, ARF. The requirement for an Asn residue
at position 7.49 for ARF-mediated coupling to PLD is shared by all GPCRs in which BFA-sensitive coupling has been studied (19). For
example, a mutant of the serotonin 5-HT2A receptor with Asp substituted for Asn7.49 retained coupling to PLC, but lost
BFA-sensitive coupling to PLD (19). This shows that the presence of a
carboxylate side chain in the 7.49 locus prevents interaction of
agonist-occupied GPCRs with the ARF·RhoA complex, regardless of the
ability to activate heterotrimeric G proteins. Computational studies of
the 5-HT2A receptor indicate that the activated receptor
conformation of the wild-type (Asn7.49) receptor differs
from that of the ARF-uncoupled N7.49D mutant in the conformation of the
activated form of the receptor, but not of the inactive
form.2 These results suggest
that the optimal receptor conformation which mediates heterotrimeric G
protein-dependent PLC coupling differs from the
conformation required for ARF-mediated PLD coupling and that the
capacity to assume a conformation for coupling to ARF requires an Asn
side chain at position 7.49.
We find that different side chain elements of the H2/H7
microdomain in the GnRH receptor are required for specific receptor functions. The GnRH receptor is unusual among GPCRs in requiring Asn
residues both at position 2.50 and position 1.50 for receptor expression, and in its transfer of the acidic residue required for
efficient PLC activation from locus 2.50 to 7.49. The presence of an
Asp side chain in position 7.49 in the wild-type GnRH receptor serves
to prevent ARF-dependent coupling to PLD, in common with other receptors which have an Asp residue in this position (19). These
findings indicate that the H2/H7 microdomain forms a critical part of
the machinery that underlies activation of the rhodopsin-like GPCRs,
and that it exhibits specific structure-related properties that are
revealed by comparison of the GnRH receptor with other GPCRs.
We gratefully acknowledge Drs. Frank
Guarnieri and Juan Ballesteros for many helpful discussions.
*
This work was supported by National Institutes of Health
Grants RO1 DK 46943 (to S. C. S.) and K05 DA00060 (to H. W.), the South African Medical Research Council, and Fogarty
International.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
||
To whom correspondence should be addressed:
Dept. of Neurology, Box 1137, Mount Sinai School of Medicine, 1 Gustave
L. Levy Place, New York, NY 10029. Tel.: 212-241-7075; Fax:
212-348-1310; E-mail: sealfon@msvax.mssm.edu.
2
K. Konvicka and H. Weinstein, unpublished results.
The abbreviations used are:
GnRH, gonadotropin-releasing hormone
(pGlu-His-Trp-Ser-Tyr-Glu-Leu-Arg-Pro-Gly-NH2);
ARF, ADP-ribosylation factor;
BFA, brefeldin A;
Bmax, maximum binding;
CCKB, cholecystokinin B;
EC50, agonist concentration that produces half-maximal stimulation;
Emax, maximum response;
GPCR, G protein-coupled
receptor;
GnRH-A, [D-Ala6,Pro9-NHEt]GnRH;
IC50, ligand concentration which inhibits binding of
125I-GnRH-A by 50%;
H, transmembrane helix;
IP, inositol
phosphate;
PLC, phospholipase C;
PLD, phospholipase D;
PtdBut, phosphatidyl butanol;
TRH, thyrotropin releasing hormone;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate.
The Functional Microdomain in Transmembrane Helices 2 and 7 Regulates Expression, Activation, and Coupling Pathways of the
Gonadotropin-releasing Hormone Receptor*
,
,
,
,
, and
§||
Department of Neurology, the
§ Fishberg Research Center in Neurobiology and the
Departments of ¶¶ Physiology and Biophysics, and
§§ Pharmacology, Mount Sinai School of Medicine, New York,
New York 10029, the ¶ Medical Research Council Brain
Metabolism Unit, 1 George Square, Edinburgh, United Kingdom EH8 9JZ,
and the ** Medical Research Council Molecular Reproductive Endocrinology
Research Unit, University of Cape Town Medical School,
Observatory, 7925 South Africa
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helices (2-6). There is a high degree of
homology within the transmembrane helices and certain amino acids are
highly conserved throughout the family (2, 3, 7). This diverse family
shares the common function of propagating a signal across lipid
membranes and the amino acid side chains which are conserved among the
GPCRs are likely to constitute key structural motifs which subserve
this universal GPCR function.
-branched, hydrophobic residue,
Ile3.54(143) (see "Experimental Procedures" for a
description of the amino acid numbering scheme). Incorporation of this
microdomain into the whole receptor model suggests that receptor
activation is accompanied by repositioning of the
Arg3.50(139) side chain, allowing it to interact with the
Asp7.49(318) side chain in transmembrane helix 7 (H7) in
the activated receptor conformation (4).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
7 M unlabeled GnRH-A.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Summary of ligand binding, immunoblot, IP accumulation, and PtdBut
accumulation assays in mutant GnRH receptors
6 M) with and without BFA (0.2 mM)
and expressed relative to the PtdBut accumulation in the absence of
GnRH and BFA.
Ligand binding of epitope-tagged GnRH receptors with mutations in H2

View larger version (26K):
[in a new window]
Fig. 1.
Immunoblot of GnRH receptor constructs.
COS-1 cells were transfected with epitope-tagged wild-type and mutant
GnRH receptor constructs as described under "Experimental
Procedures." Cell membranes were solubilized, deglycosylated,
electrophoresed, and transferred to nitrocellulose membrane as
described. Epitope-tagged receptors were detected with an antibody
generated against tetrahistidine.
Ala > Asn > Glu (Table I, Fig. 2). Immunoblot detection of the epitope-tagged H7
mutants correlated with the expression levels measured by ligand
binding (Fig. 1). The high expression of the Ala7.49(318)
and Asn7.49(318) mutants shows that the negative charge and
hydrogen bonding functions of the Asp side chain are not critical for
efficient receptor expression. In contrast, the D7.49(318)E mutant,
which conserves the carboxylate functional group, had greatly reduced
expression, both by binding (5.2% of wild-type, Table I) and by
immunoblot (Fig. 1). These results indicate that the H7 interaction
imposes specific steric constraints that are optimal for Asp and are
only poorly matched by a negatively charged side chain of a larger size. To test whether the low expression of the
Glu7.49(318) mutant was due to poor tolerance of the larger
bulk of the Glu side chain, or to misalignment of the carboxyl group,
Asp7.49(318) was substituted with Leu. The low expression
of the D7.49(318)L mutant relative to the D7.49(318)A construct (Table
I, Figs. 1 and 2) suggests that the reduced expression of the
D7.49(318)E receptor results from the increase in bulk of the side
chain and not from altered positioning of the carboxyl group.

View larger version (15K):
[in a new window]
Fig. 2.
125I-GnRH-A competition
binding. COS-1 cells were transfected with wild-type GnRH receptor
(
) or mutant constructs D7.49(318)N (
), D7.49(318)E (
),
D7.49(318)A (
), D7.49(318)L (
), and N2.50(87)D/D7.49(318)N (
)
and incubated with 125I-GnRH-A and increasing
concentrations of unlabeled GnRH-A as described under "Experimental
Procedures." Data are the mean ± S.E. of a representative
experiment performed in triplicate.

View larger version (17K):
[in a new window]
Fig. 3.
Coupling to PLC. GnRH-stimulated
accumulation of IP was measured (top panel) in COS-1 cells
transfected with wild-type (
) and D7.49(318)N (
), D7.49(318)E
(
), D7.49(318)A (
), and N2.50(87)D/D7.49(318)N (
) mutant GnRH
receptor constructs. Data are the mean ± S.E. of a representative
experiment performed in triplicate. PLC coupling efficiencies
(lower panel) were calculated from the data in Table I to
facilitate comparison of receptor-mediated activation of PLC,
independently of effects on receptor expression.

View larger version (13K):
[in a new window]
Fig. 4.
Coupling to PLD. GnRH-stimulated
accumulation of [3H]PtdBut was measured in COS-1
cells transfected with wild-type (
) and D7.49(318)N (
),
D7.49(318)E (
), and D7.49(318)A (
) mutant GnRH receptor
constructs. Transfected cells were stimulated with GnRH (1 µM) in the presence of increasing concentrations of the
ARF inhibitor, BFA. Data are the mean ± S.E. of four to ten
experiments performed in duplicate.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-adrenergic receptor.
Thus, the loss of GnRH receptors with mutations of H2 could be due
either to disruption of biosynthesis and trafficking to the membrane or
to instability and degradation of the expressed receptor.
2-adrenergic, angiotensin AT1, serotonin
5-HT2A, TRH, and NK2 tachykinin receptors (9, 10, 12, 17, 35). However, mutation of Asn7.49 to Asp had
minimal effects on the coupling of the
2-adrenergic, serotonin 5-HT2A, TRH, CCKB, and
NK2 receptors (9, 10, 12, 14, 17). The ability of Asp, but
not Ala, to substitute for the conserved Asn7.49 residue
suggests that hydrogen bonding interactions of Asn7.49 may
be required for efficient coupling of these receptors. Thus, single
site mutation experiments show that activation of these GPCRs requires
an acidic (Asp) residue in position 2.50 and a polar residue (Asn or
Asp) in the 7.49 locus. Reciprocal mutation of this microdomain in the
5-HT2A, TRH, µ-opioid, and NK2 receptors has
shown that moving the Asp side chain from H2 to H7 results in a
significant recovery of the uncoupling which results from the loss of
the Asp side chain at position 2.50 (9-12). Thus, for many GPCRs, the
presence of an Asp in the H2/H7 microdomain is required for efficient
coupling, but the Asp may be located at either position 2.50 or 7.49. In the GnRH receptor, single mutations of Asp7.49(318) show
that this receptor also requires an acidic residue for coupling to PLC
(Table I, Fig. 3). However, unlike the other GPCRs, the movement of the
Asp side chain within the microdomain (from H7 to H2 in the double
mutant) does not preserve efficient PLC coupling. Thus, in the GnRH
receptor, the Asp residue which is required for efficient coupling
appears to have been transferred from H2 to H7 in comparison with other
GPCRs. Furthermore, the GnRH receptor has fixed the requirement for the
acidic side chain at the H7 locus. The structural basis for these
unique features of the GnRH receptor may be determined by the various
non-conserved side chains that contribute to the environment of the
H2/H7 microdomain, including the special properties of the H7 structure
which, in the GnRH receptor, has 2 NP/DP motifs (18).
2-adrenergic receptor had differential effects on
different signal transduction pathways. The D2.50N mutant
2-adrenergic receptor retained the ability to mediate
inhibition of adenylyl cyclase and calcium currents, but could not
achieve the conformation necessary for activation of the distinct G
proteins that mediate activation of potassium channels (37).
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Current address: MRC Membrane and Adapter Proteins
Co-operative Group, Membrane Biology Group, Dept. of Biomedical
Sciences, Hugh Robson Bldg., George Square, Edinburgh, EH8 9XD, United Kingdom.

Current address: Medical Research Council Reproductive Biology
Unit, 37 Chalmers St., Edinburgh, EH3 9ET, United Kingdom.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sealfon, S. C.,
Weinstein, H.,
and Millar, R. P.
(1997)
Endocr. Rev.
18,
180-205 2.
Baldwin, J. M.
(1993)
EMBO J.
12,
1693-1703[Medline]
[Order article via Infotrieve]
3.
Probst, W. C.,
Snyder, L. A.,
Schuster, D. I.,
Brosius, J.,
and Sealfon, S. C.
(1992)
DNA Cell Biol.
11,
1-20[Medline]
[Order article via Infotrieve]
4.
Ballesteros, J.,
Kitanovic, S.,
Guarnieri, F.,
Davies, P.,
Fromme, B. J.,
Konvicka, K.,
Chi, L.,
Millar, R. P.,
Davidson, J. S.,
Weinstein, H.,
and Sealfon, S. C.
(1998)
J. Biol. Chem.
273,
10445-10453 5.
Schertler, G. F.,
Villa, C.,
and Henderson, R.
(1993)
Nature
362,
770-772[CrossRef][Medline]
[Order article via Infotrieve]
6.
Schertler, G. F.,
and Hargrave, P. A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11578-11582 7.
Ballesteros, J.,
and Weinstein, W.
(1995)
Methods Neurosci.
25,
366-428[CrossRef]
8.
Zhou, W.,
Flanagan, C.,
Ballesteros, J. A.,
Konvicka, K.,
Davidson, J. S.,
Weinstein, H.,
Millar, R. P.,
and Sealfon, S. C.
(1994)
Mol. Pharmacol.
45,
165-170[Abstract]
9.
Sealfon, S. C.,
Chi, L.,
Ebersole, B. J.,
Rodic, V.,
Zhang, D.,
Ballesteros, J. A.,
and Weinstein, H.
(1995)
J. Biol. Chem.
270,
16683-16688 10.
Perlman, J. H.,
Colson, A.-O.,
Wang, W.,
Bence, K.,
Osman, R.,
and Gershengorn, M. C.
(1997)
J. Biol. Chem.
272,
11937-11942 11.
Xu, W.,
Ozdener, F.,
Li, J.,
Chen, C.,
de Riel, J.,
Weinstein, H.,
and Liu-Chen, L.
(1999)
FEBS Lett.
447,
318-324[CrossRef][Medline]
[Order article via Infotrieve]
12.
Donnelly, D.,
Maudsley, S.,
Gent, J. P.,
Moser, R. N.,
Hurrell, C. R.,
and Findlay, J. B.
(1999)
Biochem. J.
339,
55-61
13.
Cook, J. V.,
Faccenda, E.,
Anderson, L.,
Couper, G. G.,
Eidne, K. A.,
and Taylor, P. L.
(1993)
J. Endocrinol.
139,
R1-4 14.
Jagerschmidt, A.,
Guillaume, N.,
Goudreau, N.,
Maigret, B.,
and Roques, B.
(1995)
Mol. Pharmacol.
48,
783-789[Abstract]
15.
Blomenrohr, M.,
Bogerd, J.,
Leurs, R.,
Schulz, R. W.,
Tensen, C. P.,
Zandbergen, M. A.,
and Goos, H. J.
(1997)
Biochem. Biophys. Res. Commun.
238,
517-522[CrossRef][Medline]
[Order article via Infotrieve]
16.
Illing, N.,
Troskie, B.,
Nahorniak, C.,
Hapgood, J.,
Peter, R.,
and Millar, R.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2526-2531 17.
Barak, L. S.,
Menard, L.,
Ferguson, S. S.,
Colapietro, A. M.,
and Caron, M. G.
(1995)
Biochemistry
34,
15407-15414[CrossRef][Medline]
[Order article via Infotrieve]
18.
Konvicka, K.,
Guarnieri, F.,
Ballesteros, J.,
and Weinstein, H.
(1998)
Biophys. J.
75,
601-611 19.
Mitchell, R.,
McCulloch, D.,
Lutz, E.,
Johnson, M.,
MacKenzie, C.,
Fennell, M.,
Fink, G.,
Zhou, W.,
and Sealfon, S.
(1998)
Nature
392,
411-414[CrossRef][Medline]
[Order article via Infotrieve]
20.
Millar, R.,
Conklin, D.,
Lofton-Day, C.,
Hutchinson, E.,
Troskie, B.,
Illing, N.,
Sealfon, S. C.,
and Hapgood, J.
(1999)
J. Endocrinol.
162,
117-126[Abstract]
21.
Zhou, W.,
Rodic, V.,
Kitanovic, S.,
Flanagan, C. A.,
Chi, L.,
Weinstein, H.,
Maayani, S.,
Millar, R. P.,
and Sealfon, S. C.
(1995)
J. Biol. Chem.
270,
18853-18857 22.
Laws, S. C.,
Beggs, M. J.,
Webster, J. C.,
and Miller, W. L.
(1990)
Endocrinology
127,
373-380[Abstract]
23.
Sealfon, S.,
Zhou, W.,
Almaula, N.,
and Rodic, V.
(1996)
Methods Neurosci.
29,
143-196
24.
Millar, R. P.,
Davidson, J.,
Flanagan, C. A.,
and Wakefield, I.
(1995)
Methods in Neurosciences, Receptor Molecular Biology
, pp. 145-162, Academic Press, San Diego
25.
Berg, K. A.,
Clarke, W. P.,
Sailstad, C.,
Saltzman, A.,
and Maayani, S.
(1994)
Mol. Pharmacol.
46,
477-484[Abstract]
26.
Mitchell, R.,
Wolbers, W. B.,
Sim, P.,
and Fennell, M.
(1995)
Biochem. Soc. Trans.
23,
208S[Medline]
[Order article via Infotrieve]
27.
Munson, P. J.,
and Rodbard, D.
(1980)
Anal. Biochem.
107,
220-239[CrossRef][Medline]
[Order article via Infotrieve]
28.
Davidson, J. S.,
Assefa, D.,
Pawson, A.,
Davies, P.,
Hapgood, J.,
Becker, I.,
Flanagan, C.,
Roeske, R.,
and Millar, R.
(1997)
Biochemistry
36,
12881-12889[CrossRef][Medline]
[Order article via Infotrieve]
29.
Suryanarayana, S.,
Daunt, D. A.,
Von Zastrow, M.,
and Kobilka, B. K.
(1991)
J. Biol. Chem.
266,
15488-15492 30.
Gether, U.,
Ballesteros, J. A.,
Seifert, R.,
Sanders-Bush, E.,
Weinstein, H.,
and Kobilka, B. K.
(1997)
J. Biol. Chem.
272,
2587-2590 31.
van Rhee, A. M.,
and Jacobson, K. A.
(1996)
Drug Dev. Res.
37,
1-38
32.
Harrison, R. W.,
and Weber, I. T.
(1994)
Protein Eng.
7,
1353-1363 33.
Davies, D. R.
(1990)
Annu. Rev. Biophys. Biophys. Chem.
19,
189-215[CrossRef][Medline]
[Order article via Infotrieve]
34.
Scheer, A.,
Fanelli, F.,
Costa, T.,
De Benedetti, P.,
and Cotecchia, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
808-813 35.
Hunyady, L.,
Bor, M.,
Baukal, A. J.,
Balla, T.,
and Catt, K. J.
(1995)
J. Biol. Chem.
270,
16602-16609 36.
Parent, J.-L.,
Le Gouill, C.,
Escher, E.,
Rola-Pleszczynski, M.,
and Stakova, J.
(1996)
J. Biol. Chem.
271,
23298-23303 37.
Surprenant, A.,
Horstman, D. A.,
Akbarali, H.,
and Limbird, L. E.
(1992)
Science
257,
977-980
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. D. G. Pfleger, A. J. Pawson, and R. P. Millar Changes to Gonadotropin-Releasing Hormone (GnRH) Receptor Extracellular Loops Differentially Affect GnRH Analog Binding and Activation: Evidence for Distinct Ligand-Stabilized Receptor Conformations Endocrinology, June 1, 2008; 149(6): 3118 - 3129. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Bee and E. C. Hulme Functional Analysis of Transmembrane Domain 2 of the M1 Muscarinic Acetylcholine Receptor J. Biol. Chem., November 2, 2007; 282(44): 32471 - 32479. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-L. Lu, M. Coetsee, C. D. White, and R. P. Millar Structural Determinants for Ligand-Receptor Conformational Selection in a Peptide G Protein-coupled Receptor J. Biol. Chem., June 15, 2007; 282(24): 17921 - 17929. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mamputha, Z.-l. Lu, R. W. Roeske, R. P. Millar, A. A. Katz, and C. A. Flanagan Conserved Amino Acid Residues that Are Important for Ligand Binding in the Type I Gonadotropin-Releasing Hormone (GnRH) Receptor Are Required for High Potency of GnRH II at the Type II GnRH Receptor Mol. Endocrinol., January 1, 2007; 21(1): 281 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
|